| Literature DB >> 33321943 |
Florie Desriac1, Abderrafek El Harras2, Matthieu Simon2, Arnaud Bondon2, Benjamin Brillet1, Patrick Le Chevalier1, Martine Pugnière3, Patrice Got4, Delphine Destoumieux-Garzón5, Yannick Fleury1.
Abstract
Discovery after discovery, host-associated microbiota reveal a growing list of positive effects on host homeostasis by contributing to host nutrition, improving hosts' immune systems and protecting hosts against pathogens. In that context, a collection of oyster associated bacteria producing antibacterial compounds have been established to evaluate their role in non-host-derived immunity. Here, we described alterins; potent anti-Gram negative compounds produced by Pseudoalteromonas hCg-6 and hCg-42 isolated from different healthy oyster hemolymph. The strains hCg-6 and hCg-42 produce a set of at least seven antibacterial compounds, ranging from 926 to 982 Da structurally characterized as cyclolipopeptides (CLPs). Alterins share the same cationic heptapeptidic cycle connected via an amido bond to different hydrophobic hydrocarbon tails. Their MICs disclosed a potent antibacterial activity directed against Gram-negative bacteria including oyster and human pathogens that may confer a beneficial defense mechanism to the host but also represents an untapped source of new antibiotics. The alterins' mechanisms of action have been deciphered: after binding to lipopolysaccharides (LPS), alterins provoke a membrane depolarization and permeabilization leading to bacterial lysis. As hCg-6 and hCg-42 produced a set of natural derivatives, the structure/activity relationship linked to the carbon tail is clarified. We showed that the hydrocarbon tail determines the LPS-binding properties of alterins and consequently their antibacterial activities. Its length and saturation seem to play a major role in this interaction.Entities:
Keywords: Pseudoalteromonas; alterin; antibiotic; cyclolipopeptides
Mesh:
Substances:
Year: 2020 PMID: 33321943 PMCID: PMC7764243 DOI: 10.3390/md18120630
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118